Salvatore Calabrese

Mr. Calabrese joined MolMed in September 2018 as Chief Financial Officer, following an extensive and significant international experience in public companies and in the biopharmaceutical sector, starting from PriceWaterhouseCooper where he was employed for seven years working in Milan, Italy and Boston, MA where, he served several clients of the biotech field listed on NASDAQ and NYSE, and subsequently at Novuspharma S.p.A., a subsidiary of Cell Therapeutics, Inc. (NASDAQ: CTIC), as Accounting & Finance Manager. From 2005 to 2014 he worked in Gentium S.p.A. (NASDAQ: GEN) where he was instrumental to the listing of the company on Nasdaq, covering various roles including Senior Vice President and Chief Financial Officer and Chief Operating Officer, supervising all of the company's corporate operations. Following the acquisition of Gentium by Jazz Pharmaceuticals (NASDAQ: JAZZ), he worked as General Manager and Site Leader for the Italian Operation at the Italian branch. He was also member of the Board of Directors of Gentium S.p.A. Jazz Pharmaceuticals Italy S.p.A. and Jazz Healthcare Italy S.r.l.